Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD

Sphygmomanometer for fibromyalgia detection in rheum OPD 🔥⬆️local pain during BP testing strongly indicates presence of FMS ✅useful, easily applicable and practical screening tool Abst#1225 #ACR22 @RheumNow

#FMF 2350 pts = 40% with arthritis - Colchicine resistance in 20% - M694V mutation carrier rate high (mutant MEFV gene) - FMF pts with arthritis have a more severe disease course - incidence of spondyloarthropathy was increased in FMF #ACR22 @RheumNow abst#1830 https://t.co/uiLhjK0UjY

Rohmer @TerrierBen et al. 196 cases of PAN from France. 28% assoc another condition - MDS and cancer mainly. Relapse in 39% - assoc age>65, GI, skin necrosis. Death assoc age>65, AKI, secondary PAN, necrotic purpura. @RheumNow #ACR22 Abstr#2232 https://t.co/fyJY9O3Gm7

Tonight! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22 https://t.co/j13W4GM56w https://t.co/fgDwPVdskC

RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.

Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa

Abstr #2192 risk of serious infxn in newborns of mothers on TNFi by placental transfer - % serious infection in TNFi in high vs low placental transfer (2.1% vs 1.6%) - HR (high vs low) 0.98 (95% CI 0.36-2.61) - No significant difference in risk of serious infxn @RheumNow #ACR22 https://t.co/7Lfpf7PERu